These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 35712773)

  • 1. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy.
    Su T; Cheng F; Qi J; Zhang Y; Zhou S; Mei L; Fu S; Zhang F; Lin S; Zhu G
    Adv Sci (Weinh); 2022 Aug; 9(23):e2201895. PubMed ID: 35712773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy.
    Su T; Liu X; Lin S; Cheng F; Zhu G
    Bioact Mater; 2023 Aug; 26():169-180. PubMed ID: 36883121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
    Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
    ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases.
    Zhou S; Cheng F; Zhang Y; Su T; Zhu G
    Acc Chem Res; 2023 Nov; 56(21):2933-2943. PubMed ID: 37802125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. pH-Responsive STING-Activating DNA Nanovaccines for Cancer Immunotherapy.
    Zhang Y; Shen T; Zhou S; Wang W; Lin S; Zhu G
    Adv Ther (Weinh); 2020 Sep; 3(9):. PubMed ID: 34337143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph node-targeting adjuvant/neoantigen-codelivering vaccines for combination glioblastoma radioimmunotherapy.
    Su T; Zhou S; Yang S; Humble N; Zhang F; Yu G; Bos PD; Cheng F; Valerie K; Zhu G
    Theranostics; 2023; 13(13):4304-4315. PubMed ID: 37649594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer.
    Zhou L; Hou B; Wang D; Sun F; Song R; Shao Q; Wang H; Yu H; Li Y
    Nano Lett; 2020 Jun; 20(6):4393-4402. PubMed ID: 32459969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering cGAS-agonistic oligonucleotides as therapeutics and vaccine adjuvants for cancer immunotherapy.
    Zhou S; Su T; Cheng F; Cole J; Liu X; Zhang B; Alam S; Liu J; Zhu G
    bioRxiv; 2023 Jul; ():. PubMed ID: 37502970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
    Li WH; Su JY; Li YM
    Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-Adjuvanted Molecular Activator (SeaMac) Nanovaccines Promote Cancer Immunotherapy.
    Luo Z; He T; Liu P; Yi Z; Zhu S; Liang X; Kang E; Gong C; Liu X
    Adv Healthc Mater; 2021 Apr; 10(7):e2002080. PubMed ID: 33336537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses.
    Taylor D; Meyer CT; Graves D; Sen R; Fu J; Tran E; Mirza B; Rodriguez G; Lang C; Feng H; Quaranta V; Wilson JT; Kim YJ; Korrer MJ
    Front Immunol; 2022; 13():936129. PubMed ID: 36059502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
    Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
    Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
    Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
    Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pH and ROS Responsiveness of Polymersome Nanovaccines for Antigen and Adjuvant Codelivery: An In Vitro and In Vivo Comparison.
    Jäger E; Ilina O; Dölen Y; Valente M; van Dinther EAW; Jäger A; Figdor CG; Verdoes M
    Biomacromolecules; 2024 Mar; 25(3):1749-1758. PubMed ID: 38236997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-Assembled STING-Activating Coordination Nanoparticles for Cancer Immunotherapy and Vaccine Applications.
    Sun X; Huang X; Park KS; Zhou X; Kennedy AA; Pretto CD; Wu Q; Wan Z; Xu Y; Gong W; Sexton JZ; Tai AW; Lei YL; Moon JJ
    ACS Nano; 2024 Apr; 18(15):10439-10453. PubMed ID: 38567994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines.
    Shae D; Baljon JJ; Wehbe M; Christov PP; Becker KW; Kumar A; Suryadevara N; Carson CS; Palmer CR; Knight FC; Joyce S; Wilson JT
    ACS Nano; 2020 Aug; 14(8):9904-9916. PubMed ID: 32701257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
    Yip T; Qi X; Yan H; Chang Y
    ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model.
    Castro Eiro MD; Hioki K; Li L; Wilmsen MEP; Kiernan CH; Brouwers-Haspels I; van Meurs M; Zhao M; de Wit H; Grashof DGB; van de Werken HJG; Mueller YM; Schliehe C; Temizoz B; Kobiyama K; Ishii KJ; Katsikis PD
    J Immunol; 2024 Feb; 212(3):455-465. PubMed ID: 38063488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Exosomes Functionalized with STING Activation for Personalized Glioblastoma Immunotherapy.
    Bao P; Gu HY; Ye JJ; He JL; Zhong Z; Yu AX; Zhang XZ
    Adv Sci (Weinh); 2024 Feb; 11(6):e2306336. PubMed ID: 38072677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.